PROGNOSTIC VALUE OF IMMUNOHISTOCHEMICAL MARKERS IN HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER
DOI:
https://doi.org/10.5281/zenodo.17233270Keywords:
Non-muscle invasive bladder cancer, p53, Ki-67, CD34, prognostic factors, angiogenesis, immunohistochemistryAbstract
Non-muscle invasive bladder cancer (NMIBC) accounts for nearly 75% of all bladder cancer cases. Despite appropriate transurethral resection of bladder tumor (TURBT) and adjuvant intravesical therapy, recurrence occurs in 50–70% of patients, and progression to muscle-invasive disease develops in 10–20%. Standard clinical prognostic factors (tumor stage, grade, multiplicity) do not fully explain the variability in outcomes. Therefore, identifying reliable molecular and morphological markers is crucial for improving patient risk stratification and developing individualized treatment strategies.
References
Бойко Е.В., Алламова Ш.М. Значение ангиогенеза в прогнозировании рецидива немышечно инвазивного рака мочевого пузыря. Доктор ахборотномаси № 3 (115)—2024, DOI: 10.38095/2181-466X-20241153-159-162
Бойко Е.В., Алламова Ш.М. Прогностическое значение ангиогенеза при немышечно-инвазивном раке мочевого пузыря. Журнал медицина и инновации №3 (15) – 2024, ISSN 2181-1873, 129-139
Kelsey, R., & Knowles, M. A. (2018). Molecular markers in bladder cancer: p53, Ki-67, and angiogenesis. BJU International, 121(4), 550–560. https://doi.org/10.1111/bju.14121
Lopez-Beltran, A., Heney, N. M., & Montironi, R. (2004). Predicting progression in non-muscle invasive bladder cancer. Urologic Oncology, 22(6), 400–408. https://doi.org/10.1016/j.urolonc.2004.04.006
Sylvester, R. J., van der Meijden, A. P. M., & Oosterlinck, W. (2006). Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables. European Urology, 49(3), 466–477. https://doi.org/10.1016/j.eururo.2005.12.031
